Partnering For Cures: What’s The Equation For Success?
This article was originally published in The Pink Sheet Daily
That helping patients ultimately will lead to return for investors was the underlying theme of this year’s Partnering For Cures conference in New York Nov. 3-5. Panels looked at issues pertaining to mental health, biotech funding, finding a cure for lupus and clinical trial protocols for cardiovascular disease.
You may also be interested in...
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?
FDA draft guidance lays out use of pathologic complete response to support accelerated approval of drugs for women with high-risk, early-stage breast cancer. Pathway allows for initial approval based on one pivotal study, which could be extended to assess survival and confirm clearance.